中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

564 records (took 0.041 seconds)

    THERAPEUTIC AND/OR PREVENTIVE AGENT COMPRISING 1-INDANSULFAMIDE DERIVATIVE FOR PAIN
    61.
    发明申请
    THERAPEUTIC AND/OR PREVENTIVE AGENT COMPRISING 1-INDANSULFAMIDE DERIVATIVE FOR PAIN 有权
    包含1-INDANSULFAMIDE衍生物用于疼痛的治疗和/或预防剂

    公开(公告)号：US20160303058A1

    公开(公告)日：2016-10-20

    申请号：US15102046

    申请日：2014-12-17

    Applicant: Eisai R&D Management Co., Ltd.

    Inventor： Hiroyuki Higashiyama ,  Yuji Kazuta ,  Keisuke Hashimoto

    IPC: A61K31/165

    CPC classification number: A61K31/165 ,  A61K31/18

    Abstract: A medicine comprising a 1-indansulfamides compound such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, or N-[(1S)-2,2-difluoro-7-methyl-2,3-dihydro-1H-indene-1-yl]sulfamide or a pharmaceutically acceptable salt thereof, has an analgesic effects in the mouse hot-plate test and rat constriction nerve injury model and thus holds promise as a therapeutic agent for acute and chronic pain.

    Abstract translation: 包含诸如N - [（1S）-2,2,5,7-四氟-2,3-二氢-1H-茚-1-基]磺酰胺的1-二氢化茚磺酰胺化合物或N - [（1S） -2,2-二氟-7-甲基-2,3-二氢-1H-茚-1-基]磺酰胺或其药学上可接受的盐在小鼠热板试验和大鼠收缩神经损伤模型中具有镇痛作用 因此作为急性和慢性疼痛的治疗剂具有希望。

    Methods for detecting Th1 cells
    62.
    发明授权
    Methods for detecting Th1 cells 有权

    公开(公告)号：US09453070B2

    公开(公告)日：2016-09-27

    申请号：US14528434

    申请日：2014-10-30

    Applicant: Eisai R&D Management Co., Ltd.

    Inventor： Keiko Yamaguchi ,  Toshio Imai ,  Kenzo Muramoto

    IPC: A61K39/395 ,  C07K16/18 ,  C07K16/28 ,  G01N33/569

    CPC classification number: C07K16/18 ,  C07K16/2803 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/76 ,  G01N33/56972 ,  G01N2333/075 ,  G01N2333/085

    Abstract: The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies. These are expected to be useful in diagnosing diseases, such as inflammation, in which infiltration of Th1 cells is involved, and in providing pharmaceutical agents for alleviating such diseases.

    Tetrahydroimidazo[1,5-d][1,4]oxazepine compound
    64.
    发明申请
    Tetrahydroimidazo[1,5-d][1,4]oxazepine compound 审中-公开
    四氢咪唑并[1,5-d] [1,4]氧氮杂化合物

    公开(公告)号：US20160052937A1

    公开(公告)日：2016-02-25

    申请号：US14830970

    申请日：2015-08-20

    Applicant: Eisai R&D Management Co., Ltd.

    Inventor： Mamoru Takaishi ,  Nobuhiro Sato ,  Takafumi Motoki ,  Tomoyuki Shibuguchi

    IPC: C07D498/04

    CPC classification number: C07D498/04

    Abstract: A compound represented by formula (I): wherein R is a methyl group or the like, R1 is a fluorine atom or the like, R2 is a hydrogen atom or a fluorine atom, R3 is a hydrogen atom, R4 is an ethyl group or the like, or a pharmaceutically acceptable salt thereof.

    Abstract translation: 由式（I）表示的化合物：其中R是甲基等，R 1是氟原子等，R 2是氢原子或氟原子，R 3是氢原子，R 4是乙基或 或其药学上可接受的盐。

    SALT OF PYRAZOLOQUINOLINE DERIVATIVE, AND CRYSTAL THEREOF
    66.
    发明申请
    SALT OF PYRAZOLOQUINOLINE DERIVATIVE, AND CRYSTAL THEREOF 有权
    盐酸吡喃衍生物及其结晶

    公开(公告)号：US20160046623A1

    公开(公告)日：2016-02-18

    申请号：US14778695

    申请日：2014-04-03

    Applicant: EISAI R&D MANAGEMENT CO., LTD.

    Inventor： Shunsuke Ozaki

    IPC: C07D471/04 ,  C07C309/29 ,  C07C57/145

    CPC classification number: C07D471/04 ,  A61K31/4745 ,  C07B2200/13 ,  C07C57/145 ,  C07C309/29

    Abstract: The present invention provides a salt of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinolin-4(5H)-one and an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, malonic acid, maleic acid, tartaric acid, methanesulfonic acid, benzenesulfonic acid and toluenesulfonic acid; or a crystal thereof with a potential to be used as drug substance in pharmaceuticals.

    Abstract translation: 本发明提供（S）-7-（2-甲氧基-3,5-二甲基吡啶-4-基）-1-（四氢呋喃-3-基）-1H-吡唑并[4,3-c]喹啉的盐 -4（5H） - 酮和选自盐酸，氢溴酸，硫酸，硝酸，磷酸，丙二酸，马来酸，酒石酸，甲磺酸，苯磺酸和甲苯磺酸的酸; 或其在药物中可能用作药物物质的晶体。

    Methods for detecting Th1 cells
    68.
    发明授权
    Methods for detecting Th1 cells 有权

    公开(公告)号：US09200066B2

    公开(公告)日：2015-12-01

    申请号：US13840851

    申请日：2013-03-15

    Applicant: Eisai R&D Management Co., Ltd.

    Inventor： Keiko Yamaguchi ,  Toshio Imai ,  Kenzo Muramoto

    IPC: C07K16/00 ,  C07K16/28 ,  C07K16/18 ,  G01N33/569

    CPC classification number: C07K16/18 ,  C07K16/2803 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/76 ,  G01N33/56972 ,  G01N2333/075 ,  G01N2333/085

    Abstract: The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies. These are expected to be useful in diagnosing diseases, such as inflammation, in which infiltration of Th1 cells is involved, and in providing pharmaceutical agents for alleviating such diseases.

    NEURAL STEM CELL HAVING INCREASED PASSAGE ABILITY, METHOD FOR MANUFACTURING NEURAL STEM CELL HAVING SAID INCREASED PASSAGE ABIILITY, AND METHOD FOR CULTURING NEURAL STEM CELLS FOR INCREASING PASSAGE ABILITY OF NEURAL STEM CELLS
    69.
    发明申请
    NEURAL STEM CELL HAVING INCREASED PASSAGE ABILITY, METHOD FOR MANUFACTURING NEURAL STEM CELL HAVING SAID INCREASED PASSAGE ABIILITY, AND METHOD FOR CULTURING NEURAL STEM CELLS FOR INCREASING PASSAGE ABILITY OF NEURAL STEM CELLS 有权
    具有增加的呼吸能力的神经干细胞，用于制造具有提高的呼吸功能的神经干细胞的方法，以及用于培养神经干细胞以增加神经干细胞的通过能力的方法

    公开(公告)号：US20150275173A1

    公开(公告)日：2015-10-01

    申请号：US14436206

    申请日：2013-10-29

    Applicant: EISAI R&D MANAGEMENT CO., LTD.

    Inventor： Norimasa Miyamoto ,  Yuichi Ono ,  Kana Namiki ,  Yoshitoshi Kasuya

    IPC: C12N5/0797

    CPC classification number: C12N5/0623 ,  C12N15/85 ,  C12N2500/14 ,  C12N2501/40 ,  C12N2501/405 ,  C12N2501/998 ,  C12N2506/00 ,  C12N2510/00

    Abstract: The object of the present invention is to provide a neural stem cell having increased passage ability, a method for manufacturing a neural stem cell having said increased passage ability, and others. The present invention, in one embodiment, provides a neural stem cell having increased passage ability having the following characteristics: (a) the N-type calcium channel gene is knocked out or knocked down in said cell, (b) the influx of Ca2+ via the N-type calcium channel is substantially absent or suppressed in said cell, (c) said cell can be passaged for at least 4 generations (more preferably 15 generations) or more, and (d) said cell maintains the differentiation potential into a nerve cell even after passage for 4 generations (more preferably 15 generations).

    Abstract translation: 本发明的目的是提供具有增加的通过能力的神经干细胞，具有所述增加的通过能力的神经干细胞的制造方法等。 在一个实施方案中，本发明提供具有增加的通过能力的神经干细胞，其具有以下特征：（a）N型钙通道基因在所述细胞中被敲除或敲低，（b）Ca 2+通过 所述细胞中N型钙通道基本上不存在或被抑制，（c）所述细胞可传代至少4代（更优选15代）或更多，和（d）所述细胞维持分化潜能为神经 细胞即使经过4代（更优选15代）。

Patent Agency Ranking